Publications

Detailed Information

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations

Cited 4 time in Web of Science Cited 6 time in Scopus
Authors

Ahn, Myung-Ju; Mendoza, Marvin Jonne L.; Pavlakis, Nick; Kato, Terufumi; Soo, Ross A.; Kim, Dong-Wan; Liam, Chong Kin; Hsia, Te-Chun; Lee, Chee Khoon; Reungwetwattana, Thanyanan; Geater, Sarayut; Chan, Oscar Siu Hong; Prasongsook, Naiyarat; Solomon, Benjamin J.; Nguyen, Thi Thai Hoa; Kozuki, Toshiyuki; Yang, James Chih-Hsin; Wu, Yi-Long; Mok, Tony Shu Kam; Tan, Daniel Shao-Weng; Yatabe, Yasushi

Issue Date
2022-12
Publisher
Cancer Information Group
Citation
Clinical Lung Cancer, Vol.23 No.8, pp.670-685
Abstract
© 2022Non-small cell lung cancer (NSCLC) is a heterogeneous disease, with many oncogenic driver mutations, including de novo mutations in the Mesenchymal Epithelial Transition (MET) gene (specifically in Exon 14 [ex14]), that lead to tumourigenesis. Acquired alterations in the MET gene, specifically MET amplification is also associated with the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in patients with EGFR-mutant NSCLC. Although MET has become an actionable biomarker with the availability of MET-specific inhibitors in selected countries, there is differential accessibility to diagnostic platforms and targeted therapies across countries in Asia-Pacific (APAC). The Asian Thoracic Oncology Research Group (ATORG), an interdisciplinary group of experts from Australia, Hong Kong, Japan, Korea, Mainland China, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam, discussed testing for MET alterations and considerations for using MET-specific inhibitors at a consensus meeting in January 2022, and in subsequent offline consultation. Consensus recommendations are provided by the ATORG group to address the unmet need for standardised approaches to diagnosing MET alterations in NSCLC and for using these therapies. MET inhibitors may be considered for first-line or second or subsequent lines of treatment for patients with advanced and metastatic NSCLC harbouring MET ex14 skipping mutations; MET ex14 testing is preferred within multi-gene panels for detecting targetable driver mutations in NSCLC. For patients with EGFR-mutant NSCLC and MET amplification leading to EGFR TKI resistance, enrolment in combination trials of EGFR TKIs and MET inhibitors is encouraged.
ISSN
1525-7304
URI
https://hdl.handle.net/10371/189407
DOI
https://doi.org/10.1016/j.cllc.2022.07.012
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share